申联生物(688098) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 30,341.47 million, a slight increase of 0.64% compared to the previous year[3] - Net profit attributable to the parent company was RMB -4,553.59 million, a decrease of 244.47% year-on-year[3] - The company reported a total asset value of RMB 155,458.29 million, down 2.47% from the beginning of the year[3] - The equity attributable to the parent company decreased by 5.25% to RMB 141,049.94 million[3] - The company expects a net profit of approximately RMB -2,100.00 million for 2024, excluding the impact of impairment[6] - The company experienced significant declines in operating profit and net profit margins due to intensified competition and falling vaccine prices[7] - Investors are advised to be cautious as the financial data is preliminary and unaudited, with final figures to be disclosed in the annual report[8] Strategic Initiatives - The company plans to enhance product competitiveness and expand sales, with new products like inactivated vaccines for foot-and-mouth disease and porcine circovirus vaccines gaining market share[5] - R&D investment increased in 2024, focusing on advanced biopharmaceutical technologies and new vaccine projects, including progress in circular mRNA vaccine development[5] Impairment and Provisions - A provision for impairment of RMB 2,817.35 million was made for certain capitalized projects due to low expected future economic benefits[6]